Are you eligible?

Are you eligible to participate in a CAM2029 clinical trial?

Clinical trial HS-18-633

Double blindA double-blind trial is one in which neither the patients nor the medical staff treating them know whether the patient is receiving the active medicine or treatment that is under investigation or a placebo. This helps to prevent bias when the results of the trial are evaluated. Placebo controlledA placebo-controlled trial is one in which, in addition to a group of patients that receive the medicine or treatment that is being investigated, a separate placebo or control group receives a placebo treatment that does not contain the active ingredient and is specifically designed to have no real effect. A placebo is used in blinded trials.

Subjects currently being treated with octreotide or lanreotide

6 monthly doses of CAM2029 or placebo

Potential for self-injection under supervision of trial personnel

Subjects with well controlled IGF-1 levels and who have not undergone radiotherapy

The effect of CAM2029 to maintain control of the disease following the subject’s previous treatment is investigated

Clinical trial HS-19-647

Open-labelAn open-label trial is one in which the patients and the medical staff treating them know which treatment the patient is receiving.

Subjects currently or previously treated with octreotide or lanreotide OR subjects treated in clinical trial HS-18-633

13 monthly doses of CAM2029
(7 monthly doses for subjects from clinical trial HS-18-633)

Potential for self-injection under supervision of trial personnel and, after being trained, at home without supervision.

Subjects do not need to have well controlled IGF-1 levels and are allowed to have undergone radiotherapy

The effect of CAM2029 to maintain control of the disease following the subject’s previous treatment or when the subject’s previous treatment is not fully controlling their disease symptoms is investigated

See if the trials are running at a clinic near you.